In the studies of tirzepatide, for example, seniors on the drug were about twice as likely to stop taking their medication because of adverse events compared with younger adults and other older adults who were in the same study but got a placebo
So maybe you see improvements in fatty liver disease or your diabetes or whatever it is
The difference between those two endpoints, 213 versus 178, could be the difference between still meeting clinical criteria for obesity and reaching a normal BMI range
10.1021/jf1019533 125 LirdprapamongkolK.SakuraiH.AbdelhamedS.YokoyamaS.MaruyamaT.AthikomkulchaiS.et al (2013)
Always verify with the specific payer how they want units reported for J3490 when tirzepatide is the drug
Research indicates that this peptide may lead to an estimated 69% increase in overall growth hormone levels, measured by the area under the curve (AUC), and a reported 55% increase in the mean pulse area of the growth hormone